Atopic Dermatitis Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight
DelveInsight has launched a new report on ”Atopic
Dermatitis Market Insights, Epidemiology, and Market Forecast-2030”.
DelveInsight’s “Atopic
Dermatitis Market Insights, Epidemiology, and Market Forecast-2030“ report
delivers an in-depth understanding of the Atopic Dermatitis (AD), historical
and forecasted epidemiology as well as the Atopic Dermatitis (AD) market
trends.
Geographies
Covered: United States, EU5 (Germany, Spain, Italy, France,
and United Kingdom), Japan and China.
- Market
analysis study carried out by DI for the period of 2017-2030 shows that
the Market size of Atopic Dermatitis was USD 2422 Million in 2017 in the
7MM
- Market
Size of Atopic Dermatitis was estimated to be 1038 USD Millions in 2017 in
the United States.
- In
the United States prevalent population of Atopic Dermatitis was found to
be 19,460,609 in 2017.
- As
per DelveInsight estimates, higher prevalent population of uncontrolled
Atopic Dermatitis is observed in United States as compared to EU5
countries and Japan.
- In
the coming years, Atopic Dermatitis (AD) market is set to change due to
the rising awareness of the disease, and incremental healthcare spending
across the world; which would expand the size of the market to enable the
drug manufacturers to penetrate more into the market
- The
companies and academics are working to assess challenges and seek
opportunities that could influence Atopic Dermatitis (AD) R&D. The
therapies under development are focused on novel approaches to
treat/improve the disease condition
- Major
players are involved in developing therapies for Atopic Dermatitis (AD).
Launch of emerging therapies will significantly impact the Atopic
Dermatitis (AD) market
- A
better understanding of disease pathogenesis will also contribute to the
development of novel therapeutics for Atopic Dermatitis (AD)
- Our
in-depth analysis of the pipeline assets across different stages of
development (Phase III and Phase II), different emerging trends and
comparative analysis of pipeline products with detailed clinical profiles,
key cross-competition, launch date along with product development
activities will support the clients in the decision-making process
regarding their therapeutic portfolio by identifying the overall scenario
of the research and development activities
“According to DelveInsight’s findings, females are
affected more as compared to males, in case of Atopic Dermatitis.”
Atopic
dermatitis (AD), also known as atopic eczema, is a type of
inflammation of the skin (dermatitis). It results in itchy, red, swollen, and
cracked skin. Clear fluid may come from the affected areas, which often
thickens over time. While the condition may occur at any age, it typically
starts in childhood with changing severity over the years. In children under
one year of age much of the body may be affected.
As children get older, the back of the knees and front of
the elbows are the most common areas affected. In adults the hands and feet are
the most commonly affected areas. Scratching worsens symptoms and affected
people have an increased risk of skin infections. Many people with atopic
dermatitis develop hay fever or asthma.
The cause is unknown but believed to involve genetics,
immune system dysfunction, environmental exposures, and difficulties with the
permeability of the skin. If one identical twin is affected, there is an 85%
chance the other also has the condition. Those who live in cities and dry
climates are more commonly affected.
Exposure to certain chemicals or frequent hand washing makes
symptoms worse. While emotional stress may make the symptoms worse. The
disorder is not contagious. The diagnosis is typically based on the signs and
symptoms.
- Pfizer
- Novartis
Pharmaceuticals
- Daiichi
Sankyo
- AbbVie
- PurGenesis
Technologies
- And
Many others
- Abrocitinib
- ZPL389
- DS-2741a
- Upadacitinib
- PUR0110
- And
Many Others
- Key
Insights
- Executive
Summary of Atopic Dermatitis (AD)
- Competitive
Intelligence Analysis for Atopic Dermatitis (AD)
- Atopic
Dermatitis (AD): Market Overview at a Glance
- Atopic
Dermatitis (AD): Disease Background and Overview
- Patient
Journey
- Atopic
Dermatitis (AD) Epidemiology and Patient Population
- Treatment
Algorithm, Current Treatment, and Medical Practices
- Unmet
Needs
- Key
Endpoints of Atopic Dermatitis (AD) Treatment
- Marketed
Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
- Emerging
Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
- Atopic
Dermatitis (AD): Seven Major Market Analysis
- Attribute
analysis
- 7MM:
Market Outlook
- Access
and Reimbursement Overview of Atopic Dermatitis (AD)
- KOL
Views
- Market
Drivers
- Market
Barriers
- Appendix
- DelveInsight
Capabilities
- Disclaimer
- About
DelveInsight
Request for Detailed TOC: https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-market
Related Reports:
Comments
Post a Comment